A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: Rationale and study protocol design for the LOGIK1702 study

Hepatic arterial infusion in combination with systemic chemotherapy in patients with hepatic metastasis from colorectal cancer: A randomized phase II study – (NCT05103020) – study protocol

7 p | 3 | 3

Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study

10 p | 23 | 2

Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: A randomized controlled trial

9 p | 13 | 2

A randomized phase II study of weekly nabpaclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: The AFUGEM GERCOR trial

11 p | 11 | 1

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

9 p | 11 | 1

Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study - SULTAN UCGI 30/PRODIGE 53 (NCT03164655) study protocol

11 p | 5 | 1

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

7 p | 9 | 1

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: A randomized phase II study

7 p | 6 | 0

A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer

8 p | 29 | 0